A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation Therapy and Celecoxib for Resectable Esophageal Cancer – HOG GI 00-16

Abstracts/Posters/Presentations:

• R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Hoosier Oncology Group GI00-16. Accepted to the general poster session at the ASCO annual meeting June 5-8, 2004, New Orleans, LA.
• Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C.Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC) Hoosier Oncology Group: GI00-16. Accepted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.

Manuscripts/Articles:

• Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Supplement Oncology News International, October 2003.
• Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, Hanna N, Stoner C, Ansari R, Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):18-21. See abstract.